ETON Eton Pharmaceuticals, Inc.
Price Chart
Executive Summary
Eton Pharmaceuticals CEO Sean Brynjelsen sold $3.82M worth of stock and CBO David Krempa sold $1.80M (including derivative exercises) in the week following the company's May 19 agreement to acquire U.S. commercialization rights to IMPAVIDO for up to $8.25M. The $4.44M total insider selling represents 0.51% of the $873M market cap, crossing the 0.5% materiality threshold. While the CEO sale is large and follows a material agreement, the cluster is entirely sells (no buys) and the historical calibration shows score-6/7 sells on this ticker have only 27-31% probability of positive T+20 outcomes, suggesting limited predictive power for downside.
Key Financial Metrics
Actionable Insight
The CEO's $3.82M sale is the largest single insider transaction in the cluster and follows a material agreement (IMPAVIDO deal) by only 9 days. While insider sells are generally weaker signals than buys, the timing and magnitude warrant monitoring for any negative developments or guidance changes at the next earnings release. The cross-filing amplifier verdicts (cluster-insider-trades + cluster-agreement-context) suggest this combination has historically been informative, but the sell-only nature and calibration data (27-31% positive T+20 probability at score 6-7) argue against overreacting.
Key Facts
- CEO Sean Brynjelsen sold 119,852 shares at $31.88 for $3.82M on 2026-05-28
- CBO David Krempa sold 57,203 shares total at ~$31.48 for $1.80M on 2026-05-26/27
- Krempa exercised 62,476 derivative shares at $0-$1.38 (non-cash and cash exercises) alongside sales
- Total insider selling of $4.44M equals 0.51% of $873M market cap
- Sales occurred 9-10 days after Eton's May 19 IMPAVIDO licensing deal (8-K filed 2026-05-19)
- No insider purchases in the cluster — 100% selling direction
- Recent 30-day insider activity shows $6.7M in total sells prior to this cluster
Financial Impact
CEO and CBO sold $4.44M combined, representing 0.51% of market cap
Risk Factors
- CEO selling $3.82M post-material-agreement could signal insider concern about deal economics or near-term outlook
- No insider buying to offset the selling — one-sided bearish signal
- CBO exercised low-cost derivatives and immediately sold, typical of compensation liquidation but adds to selling pressure
- Historical calibration shows insider sells on this ticker have poor predictive power for positive returns
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ETON-1780085946904 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
14d ago
|
Insider Cluster
| $28.68 $29.13 | ▼ −1.57% | ▼ −4.32% | $31.59 (−10.15%) |
|
May 28, 2026
15d ago
|
144
| $31.86 $27.61 | ▲ +13.34% | ▲ +13.29% | $31.59 (+0.85%) |
|
May 19, 2026
24d ago
|
8-K
| $34.45 $32.40 | ▼ −5.95% | ▼ −7.19% | $31.59 (−8.30%) |
|
Apr 27, 2026
6w ago
|
8-K
| $23.45 $30.16 | ▲ +28.61% | ▲ +28.21% | $31.59 (+34.71%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $23.45 $30.16 | ▲ +28.61% | ▲ +28.21% | $31.59 (+34.71%) |
|
Apr 16, 2026
8w ago
|
8-K
| $24.43 $22.97 | ▼ −5.98% | ▼ −6.96% | $31.59 (+29.31%) |
|
Apr 15, 2026
8w ago
|
8-K
| $24.43 $22.97 | ▼ −5.98% | ▼ −6.96% | $31.59 (+29.31%) |
|
Mar 3, 2026
14w ago
|
Press Release
| $17.53 $18.09 | ▲ +3.19% | ▲ +4.53% | $31.59 (+80.21%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $18.15 $16.70 | ▼ −7.99% | ▼ −6.78% | $31.59 (+74.05%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $18.15 $16.70 | ▼ −7.99% | ▼ −6.78% | $31.59 (+74.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access